Compare TNC & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNC | ANAB |
|---|---|---|
| Founded | 1870 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 1994 | 2015 |
| Metric | TNC | ANAB |
|---|---|---|
| Price | $86.70 | $52.91 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 12 |
| Target Price | ★ $79.00 | $71.67 |
| AVG Volume (30 Days) | 154.0K | ★ 640.4K |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.53% | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $1,137,600,000.00 | $234,603,000.00 |
| Revenue This Year | $5.77 | N/A |
| Revenue Next Year | $4.95 | $52.14 |
| P/E Ratio | $8,579.00 | ★ N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $60.18 | $17.11 |
| 52 Week High | $91.93 | $73.30 |
| Indicator | TNC | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 50.15 | 41.08 |
| Support Level | $83.41 | $52.32 |
| Resistance Level | $87.65 | $57.70 |
| Average True Range (ATR) | 2.47 | 4.98 |
| MACD | -0.19 | -1.66 |
| Stochastic Oscillator | 52.99 | 15.21 |
Tennant Co is engaged in designing, manufacturing and marketing solutions that empower customers to achieve quality cleaning performance, reduce environmental impact and help create a cleaner, safer, healthier world. The Company is committed to creating and commercializing breakthrough, sustainable cleaning innovations to enhance its broad suite of products, including floor maintenance and cleaning equipment, detergent-free and other sustainable cleaning technologies, aftermarket parts and consumables, equipment maintenance and repair service, and asset management solutions. Its products are used in many types of environments, including retail establishments, distribution centers, factories and warehouses, public venues such as arenas and stadiums, office buildings, schools, and more.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).